Business Context and Reporting Period
Company: Aclaris Therapeutics, Inc. (ACRS)
Filing Type: Form 8-K (Current Report)
Date of Report: November 4, 2020
Reporting Period: The filing announces financial results for the quarter and nine months ended September 30, 2020. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The provided text serves as a cover report referencing a press release (Exhibit 99.1) for detailed data. Consequently, specific numerical values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this document.
- Revenue/Profit: Not provided in this text.
- Cash Flow/Liquidity: Not provided in this text.
- Debt: Not provided in this text.
Material Changes
The filing text does not contain specific comparative data or descriptions of material changes versus prior periods. It solely references the issuance of a press release containing the results for the period ended September 30, 2020.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release dated November 4, 2020, which contains the management's discussion of the financial results.
Legal Disclaimer: In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 and the attached press release is not deemed "filed" under the Securities Exchange Act of 1934 and is not subject to the liability of Section 18. It is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 4, 2020) for actual financial figures, as they are not listed in the 8-K body.
- Verify the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbol ACRS on The Nasdaq Stock Market, LLC.
- Note that the financial data in this specific filing is not subject to Section 18 liability of the Exchange Act.